Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576639 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT02576639 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 124 participants.
The verdict
NCT02576639, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
Interventions
- DRUG Placebo
- DRUG CNP520
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2016-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576639
The ClinicalTrials.gov registry entry for NCT02576639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02576639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576639 about?
NCT02576639 is a clinical study titled "Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age". The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
What is the current status of trial NCT02576639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-08-10. Estimated completion is 2016-03-11.
What interventions are being tested in trial NCT02576639?
The interventions under investigation include: Placebo (DRUG), CNP520 (DRUG).
Who is sponsoring clinical trial NCT02576639?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.